CANY
CBPO

Caxton Associates (New York)’s China Biologic Products Holdings, Inc. CBPO Stock Holding History

Caxton Associates (New York)’s Portfolio CBPO Stock Details CBPO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-6,860
Closed -$701K – 590
2020
Q2 		$701K Sell
6,860
-2,587
-27% -$277K 0.06% 93
2020
Q1 		$1.02M Buy
9,447
+5,665
+150% +$651K 0.19% 60
2019
Q4 		$440K Buy
+3,782
New +$438K 0.06% 196

Other funds holding CBPO

HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
YCMGA
York Capital Management Global Advisors New York $87.8M AUM 45.55% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
MCP
Maso Capital Partners Hong Kong $60.9M AUM 0.32% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capstone Investment Advisors
Capstone Investment Advisors New York $57.4B AUM 26.91% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

Caxton Associates (New York)'s CBPO Position: Q3 2020 in Review

Caxton Associates (New York) sold out of China Biologic Products Holdings, Inc. (CBPO) in Q3 2020, closing a stake of 6,860 shares — an estimated $701K sold.

Caxton Associates (New York) first reported a position in CBPO in Q4 2019 and held it in 3 quarters. The position peaked at $1.02M in Q1 2020. 87 funds tracked by Wall St. Rank hold CBPO as of Q3 2020.

  • Caxton Associates (New York) reported no remaining China Biologic Products Holdings, Inc. position as of Q3 2020 after selling out during the quarter.
  • Caxton Associates (New York) sold 6,860 China Biologic Products Holdings, Inc. shares in Q3 2020, an estimated $701K.
  • Caxton Associates (New York) first reported a position in China Biologic Products Holdings, Inc. in Q4 2019 and held it in 3 quarters.
  • Caxton Associates (New York)'s China Biologic Products Holdings, Inc. position peaked at $1.02M in Q1 2020.
  • 87 funds tracked by Wall St. Rank held China Biologic Products Holdings, Inc. as of Q3 2020.

Based on Caxton Associates (New York)'s 13F filing for Q3 2020, filed 16 Nov 2020.